Skip to content
NEWS
EVENTS
Primary-Full-Color
  • About KCNQ2
    • What are KCNQ2-related disorders
    • Q2 Quick Notes
    • Recruiting Research Studies
    • KCNQ2 ICD Codes
    • FAQ
    • In Loving Memory
  • Caregivers
    • Newly Diagnosed
    • KCNQ2 Family Network
    • Research Where To Begin
    • Resources
    • Bi-Annual Summit
    • News & Blog
    • Patient Assistance Grant
    • Find A Doctor
    • Our Stories
  • Providers
    • Clinical Trials
    • Research Review
    • Doctor Registration
  • Research
    • For Researchers
    • Research Resources
    • Grant Program
    • For Caregivers
    • Recruiting Research Studies
    • Biorepository
  • Get Involved
    • Fundraise
    • Ways to Give
    • KCNQ2 Channel Changers
    • Volunteer
    • Awareness Week – March
    • Share Your Story
  • About Us
    • Our Role
    • Our Team
    • Scientific Advisory Board
    • Interns
    • Global Reach
    • Finances
    • Contact Us
Donate

Archive for July 2026

Quick Note #19: Redesigning Retigabine to Avoid Previous Side Effects

By Scotty Sims | July 21, 2026

Excerpt A Kv7 channel-targeting drug called retigabine was pulled from the market years ago after it resulted in some skin discoloration. Since then, it has been reformulated as azetukalner to…

Read More

Compassionate Use & Expanded Access: A Parent’s Guide

By Scotty Sims | July 7, 2026

Compassionate Use & Expanded Access: A Parent’s Guide What Is Compassionate Use / Expanded Access? Compassionate Use (officially called Expanded Access by the FDA) is a pathway that allows people…

Read More

Q2 Quick Note #18: Study Characterizes 30 Individuals With KCNQ2-Related Disorders

By Scotty Sims | July 6, 2026

Excerpt Researchers reviewed medical records of 30 individuals with KCNQ2 variants, looking for patterns in their seizures, development, and genotypes. What It’s About Most people in this study had their…

Read More

Recent Posts

  • Quick Note #19: Redesigning Retigabine to Avoid Previous Side Effects
  • Compassionate Use & Expanded Access: A Parent’s Guide
  • Q2 Quick Note #18: Study Characterizes 30 Individuals With KCNQ2-Related Disorders
  • Q2 Quick Note #17: Early Diagnosis and SCB Use Improve Seizure Control in KCNQ2-Related Disorders
  • Q2 Quick Note #16: Early EEG Patterns Identified in People With KCNQ2-DEE

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • March 2025
  • January 2025
  • October 2024
  • September 2024
  • April 2024
  • August 2022
  • June 2022
  • March 2022
  • February 2022
  • December 2021
  • October 2021
  • April 2021
  • June 2020
  • May 2020
  • March 2020
  • November 2019
  • October 2019
  • September 2019
  • April 2019
  • March 2019
  • February 2019
  • December 2018
  • September 2018
  • March 2017
  • January 2017
  • October 2016
  • May 2016
  • April 2016

KCNQ2 Cure Alliance

EIN# 47-1810644

A 501(c)(3) nonprofit organization

About Us

Research

Family Support

Events

Get Involved

Donate

Sign Up for our KCA Newsletter

Candid Transparency Seal Charity Navigator 4-star rating
info@kcnq2cure.org

info@kcnq2cure.org

3700 Quebec Street Unit 100-118 Denver, CO 80207

Privacy Policy
Terms and Condtions

©2026 KCNQ2 Cure Alliance. All Rights Reserved.

Your KCNQ2 Currants Grant application has been received.

Our current timeline for review is as follows:

  • LOI Decision: 2-3 weeks from receipt
  • Full Proposal Due: Within 3 months of invitation
  • Scientific Review: 4-5 weeks
  • Committee Review: 2 weeks
  • Applicant Notified: 5 days after review

Newsletter sign up

About You

Your Name(Required)
Your Email Address(Required)
This field is hidden when viewing the form
Your Address
This field is hidden when viewing the form